Andreasen P B, Hutters L
Acta Med Scand Suppl. 1979;624:99-105. doi: 10.1111/j.0954-6820.1979.tb00728.x.
The pharmacokinetics of paracetamol were studied in 11 patients with cirrhosis of the liver and 12 controls. The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3.7 hr vs.2.1 hr) and, correspondingly, the average plasma clearance was significantly reduced from 337 ml x min-1 in the controls to 162 ml x min-1 in the patients with cirrhosis of the liver. After subchronic dosing of paracetamol with 1 g paracetamol t. i. d. the plasma half-lives of paracetamol remained unchanged. Steady-state levels of paracetamol were significantly increased in the patients with cirrhosis of the liver. A significant correlation between the values of plasma clearance of paracetamol and prothrombin time (r = +0.88), galactose elimination capacity (r = +0.66), plasma albumin (r = +0.85) was found. No clinical or biochemical signs of hepatotoxicity were observed during the study.
对11例肝硬化患者和12名对照者进行了扑热息痛的药代动力学研究。口服1g扑热息痛后,肝硬化患者的平均生物半衰期与对照者相比显著延长(3.7小时对2.1小时),相应地,平均血浆清除率从对照者的337ml·min⁻¹显著降低至肝硬化患者的162ml·min⁻¹。以1g扑热息痛每日3次进行亚慢性给药后,扑热息痛的血浆半衰期保持不变。肝硬化患者扑热息痛的稳态水平显著升高。发现扑热息痛血浆清除率值与凝血酶原时间(r = +0.88)、半乳糖清除能力(r = +0.66)、血浆白蛋白(r = +0.85)之间存在显著相关性。研究期间未观察到肝毒性的临床或生化迹象。